YingHsuanTai

YingHsuanTai is a clinical-stage biotechnology company based in Taiwan that specializes in the development of innovative small molecule therapeutics for metabolic and chronic liver diseases. The company's primary focus is on targeting nuclear receptors and G protein-coupled receptors to address high unmet medical needs in conditions such as non-alcoholic steatohepatitis (NASH) and liver fibrosis. Their lead candidate, YHT-101, is a potent dual agonist designed to modulate metabolic pathways and reduce inflammation and fibrotic progression in the liver. YingHsuanTai aims to leverage its expertise in medicinal chemistry and disease biology to advance a pipeline of candidates through clinical validation and toward commercialization.